新冠疫情对大型美国社区人群中粪便免疫化学检测、结肠镜服务及结直肠肿瘤检出的影响
在Kaiser Permanente北加州21个医疗中心开展回顾性队列研究,比较2019与2020年粪便免疫化学检测(FIT)邮寄、完成、阳性数量及结肠镜量和结直肠肿瘤检出。2020年FIT完成数减少9.0%、阳性数减少10.1%,结肠镜总量下降26.9%,经结肠镜诊断的结直肠癌和进展期腺瘤分别减少8.7%和26.9%。
要点
- 2020年FIT邮寄量较2019年增加8.7%,但完成数减少9.0%、阳性数减少10.1%。
- 2020年4月结肠镜量较2019年4月下降79.4%,2020年全年总量下降26.9%。
- 2020年经结肠镜诊断的结直肠癌减少8.7%,进展期腺瘤减少26.9%。
核心结论
- 2020年新冠疫情导致FIT筛查和结肠镜数量较2019年减少,但居家令解除后FIT筛查量超过、结肠镜量接近2019年同期水平。
- 2020年经结肠镜诊断的结直肠癌病例总体减少8.7%。
- 这些数据可能有助于为未来国家紧急状态期间制定结直肠癌筛查和诊断检测策略提供信息。
研究设计与样本
- 在大型整合医疗组织Kaiser Permanente北加州21个医疗中心开展的回顾性队列研究。
- 纳入2019年和2020年年龄18至89岁的患者。
- 测量2020年较2019年FIT邮寄、完成和阳性数量、结肠镜数量及经结肠镜检出的结直肠肿瘤病例数的变化。
主要发现
- FIT试剂盒邮寄在2020年3月中旬至4月停止,随后回升,邮寄量较2019年增加8.7%。
- 2020年FIT完成数较2019年减少9.0%,阳性检测数较2019年减少10.1%。
- 2020年4月结肠镜量较2019年4月下降79.4%,2020年9月至12月恢复至接近疫情前水平,2020年全年结肠镜总量下降26.9%。
- 2020年经结肠镜诊断的结直肠癌患者数较2019年减少8.7%,进展期腺瘤患者数较2019年减少26.9%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The COVID-19 pandemic has affected clinical services globally, including colorectal cancer (CRC) screening and diagnostic testing. We investigated the pandemic's impact on fecal immunochemical test (FIT) screening, colonoscopy utilization, and colorectal neoplasia detection across 21 medical centers in a large integrated health care organization. METHODS: We performed a retrospective cohort study in Kaiser Permanente Northern California patients ages 18 to 89 years in 2019 and 2020 and measured changes in the numbers of mailed, completed, and positive FITs; colonoscopies; and cases of colorectal neoplasia detected by colonoscopy in 2020 vs 2019. RESULTS: FIT kit mailings ceased in mid-March through April 2020 but then rebounded and there was an 8.7% increase in kits mailed compared with 2019. With the later mailing of FIT kits, there were 9.0% fewer FITs completed and 10.1% fewer positive tests in 2020 vs 2019. Colonoscopy volumes declined 79.4% in April 2020 compared with April 2019 but recovered to near pre-pandemic volumes in September through December, resulting in a 26.9% decline in total colonoscopies performed in 2020. The number of patients diagnosed by colonoscopy with CRC and advanced adenoma declined by 8.7% and 26.9%, respectively, in 2020 vs 2019. CONCLUSIONS: The pandemic led to fewer FIT screenings and colonoscopies in 2020 vs 2019; however, after the lifting of shelter-in-place orders, FIT screenings exceeded, and colonoscopy volumes nearly reached numbers from those same months in 2019. Overall, there was an 8.7% reduction in CRC cases diagnosed by colonoscopy in 2020. These data may help inform the development of strategies for CRC screening and diagnostic testing during future national emergencies.
引用
- Lee JK, Lam AY, Jensen CD, et al. Impact of the COVID-19 Pandemic on Fecal Immunochemical Testing, Colonoscopy Services, and Colorectal Neoplasia Detection in a Large United States Community-based Population. Gastroenterology. 2022. PMID: 35580655. doi:10.1053/j.gastro.2022.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。